Business
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) (\"Protagonist\" or \"the Company\") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023.\nDetails are as follows:\nTitle: Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patientsAbstract Code: P1016Presenting Author: Andrew Kuykendall, M.D., Assistant Member, Department of Malignant Hematology, Moffitt Cancer CenterSession Date and Time: Friday, June 9, 18:00-19:00 CEST\nTitle: Pharmacokinetic and pharmacodynamic effects of rusfertide in polycythemia vera: Results from an ongoing Phase 2 study in patients with elevated hematocrit valuesAbstract Code: P1048Presenting Author: Marina Kremyanskaya, M.D., Ph.D., Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount SinaiSession Date and Time: Friday, June 9, 18:00-19:00 CEST\nFull abstract information can be found on the EHA 2023 Hybrid Congress website at https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/.\nAbout Protagonist\nProtagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 stage of development. The REVIVE study is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.\nPositive topline results from the FRONTIER 1 study of JNJ-2113 in moderate-to-severe plaque psoriasis became available in March 2023, with further details to be shared at medical meetings starting in the second quarter of 2023. Advancement of JNJ-2113 into a Phase 3 study and meeting the primary endpoint in that study would qualify Protagonist for milestone payments of $50 million and $115 million, respectively. In total, Protagonist remains eli...